Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib plus envafolimab and EP chemotherapy versus envafolimab and EP in first-line extensive-stage small cell lung cancer
ChiCTR2500099059Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Mar 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trilaciclib, envafolimab, etoposide and carboplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Incidence of grade 3 or higher neutropenia. Started Mar 2025; status: recruiting.
02
Drugs
trilaciclibenvafolimabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500099059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099059.